Anti-PD-1 and PD-L1 Antibodies in Metastatic Melanoma
- 21 November 2017
- journal article
- Published by Taylor & Francis in Melanoma Management
- Vol. 4 (4) , 175-178
Abstract
No abstract availableKeywords
Funding Information
- BMS, Novartis and Roche Genentech
This publication has 14 references indexed in Scilit:
- Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced MelanomaCancer Immunology Research, 2017
- PD-L1 Expression and Outcome of Advanced Melanoma Patients Treated with Anti-PD-1/PD-L1 Agents: A Meta-AnalysisImmunotherapy, 2016
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaJAMA, 2016
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2016
- Adaptive Immune Resistance: How Cancer Protects from Immune AttackCancer Discovery, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- IFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene ExpressionCancer Research, 2005
- Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent miceProceedings of the National Academy of Sciences, 1998